Back to Newsroom
Back to Newsroom

StockConsultant.com - breakout alert for (NASDAQ:SRPT)

Wednesday, 27 February 2013 02:28 PM

Topic:

Bridgewater, MA (February 27, 2013) - StockConsultant.com provides automated stock consulting on over 6000 US equities. Each detailed stock report contains easy to use technical analysis indicators, charts, and news to fine tune stock entry and exits. Today’s stock (NASDAQ:SRPT) is one from our daily "Stocks to Watch" list and found using the site's powerful stock screen for breakouts.

Sarepta Therapeutics Inc (NASDAQ:SRPT) founded in 1980 and is headquartered in Bothell, WA. The biopharmaceutical company is engaged in the developing of novel RNA-based therapeutics for rare and infectious diseases. SRPT has been building a base in the 25 to 30 price area for the past 3 months. The stock is has now moved above 30 and is now a confirmed breakout.

Abbreviated SRPT support and resistance map:

CURRENT PRICE 31.64, just above resistance, 29.22 ± 1.61, type triple+, strength 10

RESISTANCE ABOVE None.

SUPPORT BELOW -7.6% at 29.22 ± 1.61, type triple+, strength 10
-18.8% at 25.68 ± 1.41, type triple+, strength 10
-28.6% at 22.58 ± 1.24, type single, strength 1

SRPT Breakout details:

BREAKOUT CONFIRMED breakout above 30.81, no resistance in area just above.
Type: True breakout from triple+ resistance.
Target: 38.5, 21.7% Stop: 28.71, Loss: 9.3%, Profit/Loss ratio: 2.3 : 1 - Good

SRPT stock chart

SRPT Stock chart

Full SRPT report with stock charts and analysis here:

http://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=SRPT

To subscribe: http://www.stockconsultant.com/signup.html


Disclosure: StockConsultant.com and its employees are not registered investment advisors and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Please check with a registered investment advisor before making any investment decisions.

For full disclaimer visit: http://www.stockconsultant.com/disclaimerpage.html

 

Contact Info:

StockConsultant.com
[email protected]
774-281-3522

Topic:
Back to newsroom
Back to Newsroom
Share by: